Testosterone Replacement Therapy for Women: A Complete Clinical Guide

Testosterone is not a male hormone. That framing, inherited from the early days of endocrinology, has quietly shaped decades of medical practice in ways that have left millions of women undertreated, misdiagnosed, and dismissed. In healthy premenopausal women, the ovaries and adrenal glands produce more testosterone than estradiol by mass, and circulating testosterone exerts documented effects on libido, energy metabolism, bone density, cognitive function, and mood. Yet when testosterone declines, as it reliably does across the female lifespan, the symptom cluster it produces is routinely attributed to stress, depression, or the inevitable indignities of aging. Testosterone replacement therapy for women is one of the most evidence-supported yet under-prescribed interventions in modern women's health.

This guide examines the physiology of testosterone in women, the clinical picture of deficiency, the evidence base for replacement therapy, and the practical details of dosing and delivery that distinguish female protocols from the more familiar male counterparts. The science is more robust than many clinicians appreciate, and the gap between what research supports and what most women are offered represents one of the clearest opportunities in contemporary longevity medicine.

Why Women Need Testosterone: The Physiology

To understand why testosterone matters in women, it helps to trace its biosynthetic journey. In the female body, testosterone is produced in two locations: the theca cells of the ovarian follicle and the zona reticularis of the adrenal cortex. A significant fraction of circulating testosterone is also converted peripherally from androstenedione, a precursor that both the ovaries and adrenals secrete in quantity. From this testosterone pool, aromatase enzymes in adipose tissue, bone, breast, and brain convert a portion into estradiol, which means testosterone serves simultaneously as an active hormone in its own right and as the primary substrate for estrogen synthesis [1].

The physiological range for total testosterone in premenopausal women sits between roughly 15 and 70 nanograms per deciliter, approximately 10 to 15 times lower than typical male levels but functionally critical at those concentrations. Testosterone binds to androgen receptors expressed throughout the female body, including in the clitoris, vaginal wall, urethra, breast, bone, skeletal muscle, adipose tissue, liver, cardiovascular smooth muscle, and the central nervous system. This receptor distribution maps almost exactly onto the symptom profile women experience when testosterone falls [2].

Decline begins earlier than most women expect. Peak testosterone production in women occurs in the mid-twenties. By the late thirties, levels have often fallen by 50 percent, a trajectory driven largely by the gradual attrition of functional ovarian follicles and declining adrenal androgen output. The surgical removal of both ovaries, oophorectomy, precipitates an immediate and severe drop, sometimes by as much as 70 percent, because the ovaries contribute substantially to testosterone production even after menopause [3]. Hormonal contraceptives add a further layer of complexity: oral contraceptives containing synthetic progestins suppress LH-driven ovarian androgen production and simultaneously raise sex-hormone-binding globulin (SHBG), a carrier protein that sequesters testosterone in the bloodstream and renders it biologically inactive. The result is that some women on oral contraceptives experience a form of functional androgen deficiency even when total testosterone measures in the normal range [4].

In healthy premenopausal women, the ovaries and adrenal glands produce more testosterone than estradiol by mass — yet its deficiency remains one of the most systematically overlooked hormonal conditions in women's health.

Understanding SHBG is essential to interpreting testosterone measurements in women. Only the fraction of testosterone not bound to SHBG or albumin, termed free testosterone, is available to enter cells and activate androgen receptors. Free testosterone typically represents just 1 to 2 percent of total testosterone, and because SHBG rises with aging, thyroid disease, hepatic stress, and oral estrogen use, a woman can have a total testosterone value that appears normal while her free testosterone is profoundly deficient. Clinicians who rely solely on total testosterone without measuring SHBG and calculating free testosterone miss a substantial proportion of cases [1].

Recognizing Testosterone Deficiency in Women

No single symptom defines androgen deficiency in women, and that ambiguity has historically made diagnosis both delayed and contested. The clinical picture is a mosaic: diminished sexual desire that feels different from situational fluctuations in libido, persistent fatigue unresponsive to adequate sleep, flattening of mood without meeting criteria for clinical depression, reduced sense of vitality and drive, and increasing difficulty building or maintaining muscle mass despite consistent exercise. These complaints overlap with hypothyroidism, iron deficiency anemia, depression, sleep disorders, and the estrogen-deficiency symptoms of perimenopause, and in many women more than one process operates simultaneously [2].

Sexual dysfunction, particularly hypoactive sexual desire disorder (HSDD), has been the most studied and clinically delineated manifestation of low testosterone in women. HSDD is characterized by absent or diminished sexual desire that causes personal distress, explicitly not accounted for by relationship factors or other medical conditions. Its prevalence increases sharply across the menopausal transition, affecting an estimated 10 percent of premenopausal women and up to 40 percent of postmenopausal women, and the correlation with declining androgen levels is well established in prospective cohort data [5]. Importantly, HSDD is a diagnosis of exclusion: ruling out contributing psychological factors and ensuring adequate estrogen status before attributing the symptom to testosterone deficiency is standard clinical practice.

Beyond libido, bone health represents one of the less-discussed but clinically significant consequences of androgen deficiency in women. Androgen receptors are expressed in both osteoblasts, the bone-building cells, and osteoclasts, the cells responsible for bone resorption. Testosterone in women promotes bone mineral density through direct receptor-mediated effects on osteoblast proliferation and through aromatization to estradiol, which independently suppresses osteoclast activity. Women who have undergone surgical menopause and therefore experience abrupt androgen loss alongside estrogen withdrawal show accelerated bone mineral density loss that cannot be fully attributed to estrogen deficiency alone [3].

Cognitive symptoms, though harder to quantify, follow a recognizable pattern: impaired concentration, diminished verbal and spatial memory, and a subjective sense that mental sharpness has dulled. Androgen receptors are densely expressed in the hippocampus, prefrontal cortex, and amygdala, brain regions central to memory consolidation, executive function, and emotional regulation. Animal studies demonstrate that testosterone administration enhances spatial memory and synaptic plasticity in female rodents, and observational data in women suggest that higher endogenous androgen levels correlate with better performance on cognitive assessments, though the causal direction requires further investigation [6].

The Evidence Base: What Randomized Trials Actually Show

The clinical evidence for testosterone replacement therapy in women is more extensive than its limited regulatory approval suggests. The most comprehensive summary comes from an international expert panel convened by the International Menopause Society and published in 2019, which reviewed over 150 randomized controlled trials and concluded that testosterone therapy in postmenopausal women produces clinically significant improvements in sexual function, including desire, arousal, orgasm frequency, and sexual satisfaction [7]. That conclusion was grounded not in extrapolation from male data but in female-specific trial evidence.

An international expert panel reviewed over 150 randomized controlled trials and concluded that testosterone therapy in postmenopausal women produces clinically significant improvements in sexual desire, arousal, orgasm frequency, and overall satisfaction.

The Intrinsa trials, conducted in the early 2000s, were among the first large-scale randomized controlled trials examining transdermal testosterone in women with HSDD following surgical menopause. Women receiving a 300 microgram per day testosterone patch reported significant increases in satisfying sexual events and sexual desire scores compared with placebo, with effects persisting across 52 weeks of follow-up [5]. Notably, blood testosterone levels achieved in these trials remained within or just above the normal physiological premenopausal range, a finding that would become central to subsequent safety analyses.

Energy and mood outcomes have been harder to isolate in randomized trials partly because of the difficulty separating the effect of testosterone from concurrent improvements in sexual function and well-being. However, secondary analyses from multiple trials and several dedicated studies report improvements in general well-being, energy, and mood that appear independent of the sexual function benefit. A systematic review of eight randomized trials involving postmenopausal women found statistically significant improvements in energy and self-rated health in testosterone-treated groups compared to controls, with the caveat that blinding was imperfect in some studies given the recognizable androgenic effects like increased libido [8].

Bone density evidence is particularly compelling in surgically menopausal women. A 24-month randomized controlled trial comparing estrogen alone with estrogen plus testosterone in women following bilateral oophorectomy found superior preservation of lumbar spine and hip bone mineral density in the combination group, with a difference that translated into a meaningful reduction in fracture risk probability by FRAX modeling [3]. The mechanism involves both direct androgen receptor stimulation of osteoblasts and enhanced estradiol availability via peripheral aromatization of the administered testosterone.

Muscle mass and physical performance outcomes are emerging as an important domain. Testosterone promotes skeletal muscle protein synthesis through androgen receptor-mediated upregulation of insulin-like growth factor-1 (IGF-1) and inhibition of myostatin, a signaling protein that suppresses muscle growth. In women, randomized trials of testosterone administration demonstrate measurable increases in lean body mass and decreases in fat mass, with the lean mass gains in the range of 1 to 2 kilograms over 12 to 24 weeks [9]. In the context of longevity medicine, where sarcopenia, the age-related loss of muscle mass, is a primary determinant of late-life functional independence, this effect is more than cosmetic.

How Female TRT Differs from Male Protocols

The most consequential distinction between testosterone therapy in women and in men is the dose, and it cannot be overstated. Women require approximately 10 to 20 times less testosterone than men to achieve physiological targets. The goal in female replacement therapy is to restore levels to the upper half of the normal premenopausal range, generally 30 to 70 nanograms per deciliter of total testosterone, not to achieve supraphysiological concentrations. Protocols designed for male hypogonadism, which target total testosterone of 400 to 700 ng/dL, are entirely inappropriate for women and represent a common source of adverse effects when female patients receive under-adjusted male prescriptions [7].

The route of administration also differs in clinically important ways. Oral testosterone, which undergoes first-pass hepatic metabolism that converts it to dihydrotestosterone (DHT) and other metabolites, is generally avoided in women because it delivers an unpredictable androgenic metabolite profile and may adversely affect lipid parameters. Intramuscular injections of testosterone cypionate or enanthate, the workhorses of male TRT, produce peaks and troughs in serum concentration that are particularly problematic at female doses, where the therapeutic window is narrow enough that even modest peaks can produce virilizing side effects. At Healthspan, female patients interested in injectable testosterone can be assessed through the Testosterone Cypionate protocol, which is dose-titrated to female physiological targets under clinical supervision.

Transdermal delivery, either as a gel or cream, has become the preferred approach for most women precisely because it allows stable, titrated serum levels without the peaks of injection. Absorption varies by application site and individual skin characteristics, but clinical experience and trial data consistently show that small daily applications can maintain testosterone levels reliably within the premenopausal female range. Healthspan offers both Testosterone Topical Cream and Testosterone Gel formulations, with the specific formulation selected based on individual absorption characteristics and clinical response.

Pellet therapy, in which small crystalline testosterone implants are inserted subcutaneously and release hormone over three to six months, is available at some clinics and offers the convenience of infrequent dosing. However, pellets carry a meaningful risk of supraphysiological levels in women because the dose is fixed at insertion and cannot be easily adjusted if levels run high. Several published case series have documented androgenic side effects including acne, clitoral enlargement, and voice changes in women treated with testosterone pellets, often because the doses used were calibrated from male protocols without adequate downward adjustment [2].

Monitoring frequency also differs between male and female protocols. Because women are working with a much narrower therapeutic range and because the signs of excess, including acne, hirsutism, clitoral sensitivity changes, and voice deepening, are not always apparent until supraphysiological exposure has already occurred, more frequent laboratory monitoring is standard during the dose-titration phase. Most guidelines recommend measuring total testosterone, free testosterone, SHBG, and a complete metabolic panel at four to six weeks after initiating or changing therapy, then extending to three-monthly and eventually six-monthly intervals once stable levels are confirmed [7].

Dosing Specifics and Practical Starting Points

Establishing the right starting dose for testosterone replacement in women requires integrating baseline laboratory values, symptom severity, body weight, and the intended delivery route. For transdermal preparations, typical starting doses are in the range of 0.5 to 2 milligrams of testosterone per day, applied to thin-skinned areas such as the inner thigh, labia majora, or inner arm. This contrasts sharply with male starting doses of 50 to 100 milligrams per day, illustrating why compounded formulations at female-appropriate concentrations are generally necessary: commercially available male products are simply too concentrated to allow accurate low-dose application in women.

In practice, dose titration proceeds slowly and symptom-guided. The time course for treatment response is relevant here: libido improvements often emerge within four to six weeks, but energy, mood, and body composition changes typically take three to six months to fully manifest, reflecting the slower timescale of androgen-mediated changes in gene expression, muscle protein turnover, and neural circuitry. Patients who discontinue therapy at six weeks because they feel no different are often abandoning a treatment that would have shown clear benefit had they continued [7].

For women considering injectable protocols, subcutaneous micro-dose testosterone cypionate, administered in very small volumes (typically 0.05 to 0.1 mL of a 200 mg/mL preparation weekly) provides more stable levels than intramuscular injection because subcutaneous tissue releases the depot more slowly. This approach is gaining clinical traction precisely because weekly subcutaneous injections reduce the peak-trough variation that makes intramuscular protocols problematic in women, and because women can self-administer after appropriate training, an important practical consideration for long-term adherence.

Women who are perimenopausal or postmenopausal and considering testosterone therapy are almost always best served by addressing estrogen and progesterone status concurrently. Testosterone does not substitute for estrogen in managing vasomotor symptoms, vaginal atrophy, or bone protection in estrogen-deficient women, and the evidence for testosterone's effects on sexual function is substantially stronger in women who are adequately estrogenized. Healthspan's Women's Hormone Health program takes an integrative approach to female hormonal optimization, considering the full hormonal milieu including estradiol via the Estradiol Patch or Bi-Est 50/50 Cream and progesterone via Micronized Progesterone, rather than optimizing androgens in isolation.

Safety Profile and Addressing the Breast Cancer Question

The safety of testosterone therapy in women is the question that most directly shapes clinical decision-making, and it deserves a careful, evidence-grounded answer rather than reflexive caution. The most frequently raised concern involves breast cancer risk. The short answer, supported by the current weight of evidence, is that testosterone replacement at physiological doses does not appear to increase breast cancer risk and may have a protective effect in certain contexts, though long-term data beyond five years are limited [7].

The mechanistic basis for a potential protective effect is rooted in the direct action of testosterone on androgen receptors expressed in breast epithelial cells, where androgen receptor signaling tends to suppress proliferation rather than promote it. The concern about testosterone converting to estradiol via aromatase and thereby stimulating estrogen-sensitive breast tissue is theoretically valid, but at physiological replacement doses, the additional estradiol generated from exogenous testosterone is small relative to the endogenous estradiol background, particularly in women who are already receiving estrogen therapy [2].

Observational data from large cohorts do not show an increased breast cancer incidence in women with higher endogenous testosterone levels, and several studies report an inverse association between androgen levels and breast cancer risk in postmenopausal women, though confounding limits causal inference [10]. A large prospective cohort study of women receiving testosterone pellets found no increased incidence of breast cancer over a mean follow-up of several years, and some investigators have proposed that the anti-proliferative effect of testosterone may partially explain why combined estrogen-testosterone therapy in some studies shows lower breast cancer rates than estrogen alone, a hypothesis that requires confirmation in randomized trials before clinical use as a cancer-reduction strategy.

Cardiovascular safety in women is a nuanced area. Testosterone in men at supraphysiological doses, as seen in anabolic steroid use, produces well-documented adverse effects on HDL cholesterol, red blood cell mass (polycythemia), and thrombotic risk. At physiological replacement doses in women, however, the lipid effects are generally neutral or slightly favorable, with some studies reporting modest improvements in insulin sensitivity, a clinically meaningful benefit given the cardiometabolic changes that accompany menopause [7]. Hematocrit elevation, a primary safety concern in male TRT, is rarely clinically significant at female doses because the starting hematocrit in women is lower and the dose-dependent erythropoietic effect is proportionally smaller.

Androgenic side effects, including acne, increased body or facial hair growth, and clitoral sensitivity, occur in a dose-dependent manner and represent the clearest signal that testosterone levels are running supraphysiological. Their emergence is an indication to reduce the dose rather than to discontinue therapy entirely. Voice deepening is the one androgen effect that can be irreversible and must be actively monitored, though it is exceptionally rare when therapy is maintained within the physiological female range [7].

Testosterone replacement at physiological doses does not appear to increase breast cancer risk and may have a protective effect in certain contexts — a conclusion supported by over 150 randomized controlled trials reviewed by international expert consensus.

The Regulatory Gap and the Clinical Reality

In most countries, including the United States, there is no FDA-approved testosterone product for women. This regulatory gap does not reflect the evidence; it reflects commercial and historical factors. Pharmaceutical companies that developed female testosterone products, including the Intrinsa patch that showed clear efficacy in the pivotal trials, faced FDA non-approval decisions based largely on concerns about long-term safety data gaps rather than evidence of harm, a distinction that matters enormously for clinical interpretation [2].

In practice, clinicians who treat women with testosterone in the United States do so through off-label prescribing, which is entirely legal and common across many domains of medicine, using either compounded preparations formulated at female-appropriate doses or male products prescribed at fractions of the labeled dose. The International Society for the Study of Women's Sexual Health (ISSWSH) and the International Menopause Society (IMS) both publish clinical practice recommendations supporting the use of testosterone for postmenopausal women with HSDD, providing a robust expert consensus framework for off-label practice [7].

Australia represents a notable exception: Testosterone Cream (AndroFeme 1%) received regulatory approval from the Therapeutic Goods Administration specifically for women, with a labeled indication for low sexual desire in postmenopausal women. Its availability provides a useful model for what female-specific testosterone regulation looks like in practice, and several clinical trials conducted with this preparation have contributed meaningfully to the evidence base [2].

The regulatory gap has practical consequences for women seeking treatment. It creates a landscape in which access depends heavily on finding a clinician familiar with off-label androgen prescribing in women, navigating pharmacy compounding, and managing out-of-pocket costs because most insurance plans in the United States do not cover testosterone therapy for women. Telehealth longevity practices that specialize in hormonal optimization have meaningfully expanded access by combining remote consultation with laboratory-guided protocols and compounded preparations shipped to patients, a model that the evidence supports as clinically viable when appropriate monitoring is built into the protocol.

Testosterone in the Context of Female Longevity

Framing testosterone therapy purely as a treatment for sexual dysfunction undersells its significance in the longevity medicine context. The age-related decline in female androgens contributes to at least four of the canonical hallmarks of aging: reduced muscle mass (sarcopenia), decreased bone mineral density (osteopenia progressing to osteoporosis), increased adiposity particularly visceral fat accumulation, and possibly accelerated cognitive decline. Each of these trajectories is amenable to modification, and testosterone's role in modifying them positions it alongside estrogen, vigorous resistance exercise, and adequate dietary protein as one of the foundational interventions in women's longevity medicine [9].

The muscle-testosterone connection in women deserves particular emphasis because it links directly to late-life independence. Skeletal muscle mass peaks in the late twenties and declines at roughly 1 percent per year thereafter, accelerating after menopause. Women who enter their sixties with low muscle mass face substantially elevated risk of falls, fractures, metabolic dysfunction, and dependency. Testosterone's anabolic effect on muscle, mediated through androgen receptor activation in myocytes and downstream increases in muscle protein synthesis, provides a physiological mechanism that resistance training alone, while critically important, cannot fully replicate in the setting of hormonal deficiency [9].

Metabolic health represents another intersection between testosterone biology and longevity. Women with higher androgen levels tend to show better insulin sensitivity, lower fasting glucose, and more favorable body composition. The directionality here is complicated because insulin resistance can itself suppress SHBG and alter androgen metabolism, but several intervention studies demonstrate that testosterone administration in androgen-deficient women improves markers of insulin sensitivity independent of weight change, a finding consistent with androgen receptor signaling in skeletal muscle promoting glucose uptake [7].

The cognitive dimension of female androgen biology is an area of active investigation with significant longevity implications. The observation that Alzheimer's disease disproportionately affects women, with roughly two-thirds of Alzheimer's diagnoses occurring in women, has prompted investigation into the hormonal contributors to this disparity. Estrogen neuroprotection has been the dominant hypothesis, but emerging research suggests that androgens, which decline earlier than estrogens across the female lifespan, may contribute independently to cognitive resilience. Androgen receptors in the hippocampus and prefrontal cortex modulate synaptic plasticity, neurotrophin signaling, and amyloid precursor protein processing, all pathways relevant to Alzheimer's pathophysiology [6]. Clinical trials specifically powered to test testosterone's effect on cognitive outcomes in women are underway, and their results are likely to refine practice significantly.

Who Is a Candidate? Clinical Assessment and the Decision Framework

Identifying appropriate candidates for testosterone replacement therapy in women begins with a thorough hormonal history, symptom inventory, and laboratory assessment. Women most likely to benefit are those with documented low or low-normal testosterone levels, particularly low free testosterone when SHBG is elevated, who report one or more of the characteristic symptoms: diminished sexual desire, persistent fatigue not explained by sleep or thyroid dysfunction, difficulty maintaining muscle mass despite appropriate exercise and protein intake, or mood changes characterized by flatness, low drive, and reduced sense of wellbeing rather than classic depressive symptoms.

Laboratory assessment should include total testosterone measured by a high-quality platform, ideally mass spectrometry-based assay rather than immunoassay, which is unreliable at the low concentrations typical in women. SHBG, free testosterone (calculated), LH, FSH, estradiol, progesterone (if premenopausal), cortisol (to exclude adrenal pathology), thyroid function, and a complete metabolic panel including lipids provide the baseline necessary for safe prescribing and monitoring. In women with unexpectedly low testosterone before age 40, assessment for premature ovarian insufficiency and adrenal disease is warranted before attributing the deficiency to normal physiological aging [2].

Contraindications to testosterone therapy in women include active breast cancer or other androgen-sensitive malignancy, pregnancy or planned pregnancy (testosterone is teratogenic in female fetuses and reliable contraception is required in premenopausal women), untreated polycythemia vera, and severe hepatic impairment. Prior breast cancer in remission is a relative contraindication where individualized risk-benefit discussion is warranted, particularly given emerging data suggesting that androgen receptor signaling may be antagonistic to estrogen receptor-driven breast cancer proliferation in certain molecular subtypes [7].

Women who are premenopausal and considering testosterone therapy for symptoms like low libido and fatigue require particular attention to contraception, as testosterone can suppress ovulation unpredictably and, more importantly, is not a reliable contraceptive itself. The teratogenic risk to a female fetus exposed to supraphysiological androgens in utero, including the risk of virilization, is well established in congenital adrenal hyperplasia and must be taken seriously in the therapeutic context.

Integrating Testosterone into a Comprehensive Longevity Protocol

Testosterone therapy does not operate in a vacuum, and its effects are modulated by lifestyle variables that either amplify or attenuate its benefits. Resistance training and testosterone replacement are synergistic: the anabolic signaling from mechanical loading of muscle and the hormonal signaling from testosterone both converge on the same downstream pathways, including mTOR activation and muscle protein synthesis, producing greater lean mass gains in combination than either achieves independently. Women who engage in structured resistance exercise two to three times weekly alongside testosterone therapy consistently show superior body composition outcomes compared to those who rely on hormone therapy without exercise [9].

Adequate dietary protein is the third component of this synergistic triad. Testosterone promotes muscle anabolism, and resistance exercise provides the stimulus, but without sufficient amino acid substrate, particularly leucine, the translation of anabolic signaling into actual muscle protein synthesis is rate-limited. Current evidence supports protein intake of 1.6 to 2.2 grams per kilogram of body weight per day for women seeking to preserve or build muscle mass in the context of hormonal optimization, substantially above the commonly cited dietary reference intake of 0.8 grams per kilogram.

Sleep quality profoundly affects androgen physiology in both directions: poor sleep impairs testosterone production, and low testosterone disrupts sleep architecture, particularly reducing restorative slow-wave sleep. Addressing obstructive sleep apnea, which is under-diagnosed in women, and optimizing sleep hygiene are therefore integral components of any hormonal optimization program. The clinical strategy is to address the most impactful modifiable factor first and reassess hormone levels after stabilizing sleep, because testosterone measurements taken in the context of chronic sleep deprivation may underestimate baseline androgen capacity.

Stress and cortisol bear mention because the adrenal cortex, the organ that synthesizes both cortisol and adrenal androgens including DHEA and DHEA-sulfate, is subject to a prioritization effect under chronic stress conditions. When cortisol demand is persistently elevated, pregnenolone, the common biosynthetic precursor, is shunted preferentially toward cortisol production at the expense of androgen synthesis, a phenomenon sometimes called the pregnenolone steal. While the clinical magnitude of this effect in humans remains debated, the association between chronic psychological stress and lower DHEA-S levels is well documented, and stress reduction as a component of hormonal optimization is grounded in endocrine physiology rather than mere wellness convention.

The Future of Female Testosterone Therapy

Several developments are likely to reshape the clinical landscape for testosterone replacement therapy in women over the next decade. Regulatory pathways for female-specific testosterone products are under active consideration in multiple jurisdictions, driven partly by the ISSWSH and IMS consensus statements and partly by a broader recognition that the absence of approved products has created an inequitable access situation compared to male hypogonadism. If a regulatory approval follows for a compounded or commercial transdermal testosterone product specifically labeled for women, it would dramatically expand prescriber comfort and insurance coverage.

The development of selective androgen receptor modulators (SARMs) represents a parallel research track with particular relevance for women. SARMs are designed to activate androgen receptors in target tissues, such as muscle and bone, while minimizing activity in tissues associated with androgenic side effects, such as the pilosebaceous unit responsible for acne and hair growth. If tissue-selective androgen signaling can be achieved pharmacologically, women who are deterred by the androgenic side effect profile of conventional testosterone may have access to agents that deliver the anabolic and protective benefits without the virilizing risks. Several SARMs have completed early-phase trials in women, though none has yet achieved regulatory approval [11].

Long-term safety data remain the most significant evidence gap. The existing randomized controlled trial literature is dominated by studies of 12 to 24 months' duration, which are sufficient to establish short-term efficacy and identify early adverse effects but cannot address whether decades of testosterone replacement modify breast cancer risk, cardiovascular outcomes, or cognitive trajectories. Observational cohort studies will continue to provide the longer-term signal while prospective trials of extended duration are designed. Women and their clinicians must weigh this evidence gap honestly, recognizing that the absence of evidence for long-term safety is not evidence of long-term harm, but neither is it reassurance.

What is clear now is that testosterone is a biologically essential hormone in women, that its decline is clinically consequential across multiple organ systems, and that evidence-based replacement at physiological doses is both effective and reasonably safe for well-selected candidates. The conversation about women's hormonal health has been dominated for decades by estrogen. Adding testosterone to that conversation, with the same rigor and clinical respect accorded to other evidence-based interventions, is a necessary correction.